Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment

References

• Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650–4658.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrinol Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691–697.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588–4593.
   PubMed Web of Science ®Google Scholar
• Vincent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003;111: 1372–1380.
   Web of Science ®Google Scholar
• Bernini GP, Sgro' M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999;84:2008–2012.
   PubMed Web of Science ®Google Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocrinol Rev 2003;24:183–217.
   PubMed Web of Science ®Google Scholar
• Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF. Obesity and the polycystic ovary syndrome. Minerva Endocrinol 2007;32:129–140.
   PubMedGoogle Scholar
• Cooke JP. Asymmetrical dimethylarginine: the Uber marker. Circulation 2004;109:1813–1819.
   PubMed Web of Science ®Google Scholar
• Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420–1426.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Pektas M, Tonguc E, Kilic S, Gulerman C, Gungor T, Mollamahmutoglu L. The correlation of plasma homocysteine with insulin resistance in polycystic ovary syndrome. J Obstet Gynaecol Res 2008;34:384–391.
   PubMed Web of Science ®Google Scholar
• Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Proven and potential benefits. Hum Reprod 2002;17:2230–2236.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond Engl) 2010;6:577–593.
   PubMedGoogle Scholar
• Stefano P, Angela F, Fulvio Z, Francesco O Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1–50.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in nondiabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997;57:521–527.
   PubMed Web of Science ®Google Scholar
• Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S. Homocysteine levels in women with PCOS treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005;20:894–899.
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003;168:351–358.
   PubMed Web of Science ®Google Scholar
• Giallauria F, Orio F, Lombardi G, Colao A, Vigorito C, Tafuri MG, Palomba S. Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study. J Ovarian Res 2009;2:3.
   PubMed Web of Science ®Google Scholar
• Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670.e1–670.e7. discussion 670:7–10.
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001;76:326–331.
   PubMed Web of Science ®Google Scholar
• Trivax B, Azziz R. Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:168–177.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenc G, Can G. Prospective validation in i»dentical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007;7:29–34.
   PubMedGoogle Scholar
• Matthews DR, Hosker JP, Rudenski A, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function in man. Diabeteologia 1985;28:401–411.
   PubMed Web of Science ®Google Scholar
• Cibula D. Is insulin resistance an essential component of PCOS? Hum Reprod 2004;9:757–759.
   Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. I. Diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999.
   Google Scholar
• Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82–90.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril 2008;93:184–191.
   PubMed Web of Science ®Google Scholar
• Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007;22:1200–1209.
   PubMed Web of Science ®Google Scholar
• Frempong BA, Ricks M, Sen S, Sumner AE. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 2008;93:2097–2103.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471–478.
   PubMed Web of Science ®Google Scholar
• Pongchaidecha M, Srikusalanukul V, Chattananon R, Tangariyaporn S. Effect of metformin on plasma homocysteine, vitamin B12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. J Med Assoc Thai 2004;87:780–787.
   PubMedGoogle Scholar
• Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998;244:169–174.
   PubMed Web of Science ®Google Scholar
• Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 2008;111:857–864.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, Matíes M, Escobar-Morreale HF. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009;160:469–480.
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, nonobese subjects. Atherosclerosis 1998;139:197–198.
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol 2004;60:560–567.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471–478.
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82:3074–3077.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161–3168.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, et al. 2005. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2000;90:2–5.
   PubMed Web of Science ®Google Scholar
• Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008;24:378–384.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. Creactive protein before and after weight loss in obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2944–2951.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009;91:213–219.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894–1901.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148–156.
   PubMed Web of Science ®Google Scholar
• Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitizing drugs versus the combined oral $132#contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;24:1.
   Google Scholar